Microbot Medical Inc. (MBOT)
- Previous Close
0.8772 - Open
0.8700 - Bid 0.8375 x 100
- Ask 0.9205 x 100
- Day's Range
0.8610 - 0.8806 - 52 Week Range
0.8600 - 4.3700 - Volume
31,607 - Avg. Volume
101,125 - Market Cap (intraday)
12.671M - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0500 - Earnings Date May 15, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
www.microbotmedical.comRecent News: MBOT
Performance Overview: MBOT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBOT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBOT
Valuation Measures
Market Cap
12.67M
Enterprise Value
6.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.96%
Return on Equity (ttm)
-182.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.74M
Diluted EPS (ttm)
-1.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
6.38M
Total Debt/Equity (mrq)
5.13%
Levered Free Cash Flow (ttm)
-3.81M